Poland· PL-100326840
Synagis
A palivizumab product containing palivizumabum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
URPL (Poland)- Active substance
- Palivizumabum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin08054083006093
- gtin08054083006109
- gtin05000456067720
- gtin05000456067713
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwaySynagisAstraZeneca
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
- CzechiaSYNAGISAstraZeneca AB, Södertälje
- BelgiumSynagis 100 mg/mlAstraZeneca
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- IcelandSynagisAstraZeneca AB*
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- FinlandSynagisAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2aada32a-a5e0-43eb-9a07-cef0d7df3f86 GET /v1/drugs/2aada32a-a5e0-43eb-9a07-cef0d7df3f86?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "08054083006093 ¦ Rp ¦ Skasowane ¦ EU/1/99/117/003 ¦ 104380\n1 fiol. 0,5 ml\n08054083006109 ¦ Rp ¦ Skasowane ¦ EU/1/99/117/004 ¦ 104381\n1 fiol. 1 ml\n05000456067720 ¦ Rp ¦ EU/1/99/117/003 ¦ 139935\n1 fiol. 0,5 ml\n05000456067713 ¦ Rp ¦ EU/1/99/117/004 ¦ 139936\n1 fiol. 1 ml",
"substance": "Palivizumabum 100 mg/ml",
"common_name": "Palivizumabum",
"pl_product_id": "100326840",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.